Motley Fool Asset Management LLC Has $3.06 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Key Points

• Motley Fool Asset Management LLC increased its stake in Ultragenyx Pharmaceutical by 74.4% during the first quarter, owning 84,473 shares valued at about $3.06 million.
• Several institutional investors have also raised their stakes, with 97.67% of Ultragenyx's shares now owned by institutional players.
• Ultragenyx reported earnings of ($1.17) per share, which was better than expected, with quarterly revenue of $166.50 million, indicating a 13.2% increase compared to the prior year.

Motley Fool Asset Management LLC increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 74.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,473 shares of the biopharmaceutical company's stock after acquiring an additional 36,025 shares during the period. Motley Fool Asset Management LLC owned approximately 0.09% of Ultragenyx Pharmaceutical worth $3,059,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Nuveen LLC acquired a new stake in Ultragenyx Pharmaceutical during the 1st quarter valued at $18,776,000. Entropy Technologies LP purchased a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter worth $273,000. Covestor Ltd raised its position in shares of Ultragenyx Pharmaceutical by 86.8% in the 1st quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company's stock worth $62,000 after buying an additional 795 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Ultragenyx Pharmaceutical by 66.2% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 44,901 shares of the biopharmaceutical company's stock valued at $1,626,000 after purchasing an additional 17,885 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Ultragenyx Pharmaceutical by 8.4% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,342 shares of the biopharmaceutical company's stock valued at $230,000 after purchasing an additional 493 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Price Performance

RARE stock traded up $0.73 during trading hours on Friday, reaching $29.74. The stock had a trading volume of 654,335 shares, compared to its average volume of 1,293,021. The stock has a market capitalization of $2.87 billion, a PE ratio of -5.37 and a beta of 0.25. The stock has a 50-day simple moving average of $32.67 and a 200 day simple moving average of $36.35. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $25.81 and a fifty-two week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The company had revenue of $166.50 million during the quarter, compared to analysts' expectations of $161.37 million. During the same quarter last year, the company posted ($1.52) EPS. Ultragenyx Pharmaceutical's quarterly revenue was up 13.2% compared to the same quarter last year. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the transaction, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. This trade represents a 13.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

RARE has been the subject of several recent analyst reports. Guggenheim restated a "buy" rating and set a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Canaccord Genuity Group cut their price target on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Wedbush cut their price target on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a report on Monday, July 14th. HC Wainwright raised Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 price target on the stock in a report on Monday, July 28th. Finally, Cantor Fitzgerald cut their price target on Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating on the stock in a report on Wednesday, August 6th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $81.50.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.